Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, SLP, 78210, México, Mexico.
Vaccine. 2013 Feb 27;31(10):1364-9. doi: 10.1016/j.vaccine.2013.01.005. Epub 2013 Jan 11.
Alternatives to pharmacological treatments for atherosclerosis are highly desirable in terms of cost and compliance. During the last two decades several vaccination strategies have been reported as an effort to develop immunotherapeutic treatments. This approach consists on eliciting immune responses able to modulate either the atherosclerosis-associated inflammatory processes or the activity of some physiological mechanisms that are up-regulated under this pathologic condition. In particular, the apolipoprotein B100 (ApoB100) and the cholesterilester transferase protein (CETP) have been targeted in these strategies. It is considered that recent progress in the development of experimental models of oral vaccines against atherosclerosis has opened a new avenue in the field: as plant-based vaccines are considered a viable platform for vaccine production and delivery at low costs, they could serve as an oral-delivered therapeutic approach for atherosclerosis in an economical and patient-friendly manner. The rationale of the design, development and evaluation of possible plant-based vaccines against atherosclerosis is discussed in this review. We identify within this approach a significant trend that will positively impact the field of atherosclerosis vaccination.
在成本和依从性方面，替代动脉粥样硬化的药物治疗方法是非常可取的。在过去的二十年中，已经有几种疫苗接种策略被报道作为开发免疫治疗方法的努力。这种方法包括诱导能够调节动脉粥样硬化相关炎症过程或调节在这种病理条件下上调的某些生理机制活性的免疫反应。特别是，载脂蛋白 B100（ApoB100）和胆固醇酯转移蛋白（CETP）已成为这些策略的靶点。人们认为，针对动脉粥样硬化的口服疫苗实验模型的最新进展为该领域开辟了新的途径：由于植物性疫苗被认为是一种具有成本效益的疫苗生产和输送的可行平台，因此它们可以作为一种经济且患者友好的方式用于动脉粥样硬化的口服治疗方法。本文讨论了针对动脉粥样硬化的可能植物性疫苗的设计、开发和评估的基本原理。我们在这种方法中发现了一个重要趋势，它将对动脉粥样硬化疫苗接种领域产生积极影响。
